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Functional Proteomics Identifies Acinus L as a
Direct Insulin- and Amino Acid-Dependent
Mammalian Target of Rapamycin Complex 1
(mTORC1) Substrate*□S
Jennifer Jasmin Schwarz‡§¶, Heike Wiese§, Regine Charlotte To¨lle‡§, Mostafa Zarei**,
Jo¨rn Dengjel¶**, Bettina Warscheid§¶**¶¶, and Kathrin Thedieck‡**‡‡§§¶¶
The serine/threonine kinase mammalian target of rapa-
mycin (mTOR) governs growth, metabolism, and aging in
response to insulin and amino acids (aa), and is often
activated in metabolic disorders and cancer. Much is
known about the regulatory signaling network that en-
compasses mTOR, but surprisingly few direct mTOR sub-
strates have been established to date. To tackle this gap
in our knowledge, we took advantage of a combined
quantitative phosphoproteomic and interactomic strat-
egy. We analyzed the insulin- and aa-responsive phos-
phoproteome upon inhibition of the mTOR complex 1
(mTORC1) component raptor, and investigated in parallel
the interactome of endogenous mTOR. By overlaying
these two datasets, we identified acinus L as a potential
novel mTORC1 target. We confirmed acinus L as a direct
mTORC1 substrate by co-immunoprecipitation and MS-
enhanced kinase assays. Our study delineates a triple
proteomics strategy of combined phosphoproteomics, in-
teractomics, and MS-enhanced kinase assays for the de
novo-identification of mTOR network components, and
provides a rich source of potential novel mTOR interac-
tors and targets for future investigation. Molecular &
Cellular Proteomics 14: 10.1074/mcp.M114.045807, 2042–
2055, 2015.
The serine/threonine kinase mammalian target of rapamy-
cin (mTOR)1 is conserved in all eukaryotes from yeast to
mammals (1). mTOR is a central controller of cellular growth,
whole body metabolism, and aging, and is frequently dereg-
ulated in metabolic diseases and cancer (2). Consequently,
mTOR as well as its upstream and downstream cues are
prime candidates for targeted drug development to alleviate
the causes and symptoms of age-related diseases (3, 4). The
identification of novel mTOR regulators and effectors thus
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1 The abbreviations used are: mTOR, mammalian target of rapa-
mycin; 4E-BP, 4E-binding protein; aa, amino acid; acinus / ACIN1,
apoptotic chromatin condensation inducer in the nucleus; AGC ki-
nase, kinase of protein kinase A, G, C families; AHNAK, neuroblast
differentiation-associated protein AHNAK; AMPK, AMP-dependent
kinase; ASAP, apoptosis- and splicing-associated protein; AUC
FW5PM, area under the curve, full width at 5% peak height; BCLAF1,
bcl-2-associated transcription factor 1; CAD, carbamoyl-phosphate
synthetase 2, aspartate transcarbamoylase, dihydroorotase; Deptor,
DEP domain-containing mTOR-interacting protein; eIF4G, translation
initiation factor 4G; EJC, exon junction complex; Grb10, growth factor
receptor-bound protein 10; IPTG, isopropyl -D-1-thiogalactopyra-
noside; IR, insulin receptor; IRS, insulin receptor substrate; ITRAQ,
isobaric tags for relative and absolute quantitation; LFQ, label-free
quantification; MEF, mouse embryonic fibroblasts; mLST8/GbetaL,
target of rapamycin complex subunit LST8/ G protein beta subunit-
like; mSIN1, target of rapamycin complex 2 subunit MAPKAP1;
mTORC1, mTOR complex 1; NFL, negative feedback loop; PDK1,
phosphoinositide-dependent protein kinase 1; PI3K, phosphatidyli-
nositide 3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate;
PKC, protein kinase C; PLEC, plectin; PRAS40, proline-rich AKT1
substrate 1; PRR5/L, proline-rich protein 5/-like; Raptor, regulatory-
associated protein of mTOR; Rheb, ras homolog enriched in brain;
Rictor, rapamycin-insensitive companion of mammalian target of ra-
pamycin; RPS6, ribosomal protein 6; RSK1, ribosomal S6 kinase 1;
S6K, S6-kinase; SDC, sodium deoxycholate; SGK, serum and gluco-
corticoid kinase; SILAC, stable isotope labeling by amino acids in cell
culture; SLK, STE20-like serine/threonine-protein kinase; SPTBN1,
spectrin beta chain, brain 1; TiO2, titanium dioxide; TSC, tuberous
sclerosis complex; XIC, extracted ion chromatogram.
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remains a major goal in biomedical research. A vast body of
literature describes a complex signaling network around
mTOR. However, our current comparatively detailed knowl-
edge of mTOR’s upstream cues contrasts with a rather limited
set of known direct mTOR substrates.
mTOR exists in two structurally and functionally distinct
multiprotein complexes, termed mTORC1 and mTORC2. Both
complexes contain mTOR kinase as well as the proteins
mLST8 (mammalian lethal with SEC thirteen 8) (5–7), and
deptor (DEP domain-containing mTOR-interacting protein)
(8). mTORC1 contains the specific scaffold protein raptor
(regulatory-associated protein of mTOR) (9, 10), whereas
mTORC2 contains the specific binding partners rictor (rapa-
mycin-insensitive companion of mTOR) (5–7), mSIN1 (TORC2
subunit MAPKAP1) (11–13), and PRR5/L (proline rich protein
5/-like) (14–16). The small macrolide rapamycin acutely inhib-
its mTORC1, but can also have long-term effects on mTORC2
(17, 18). More recently, ATP-analogs (19) that block both
mTOR complexes, such as Torin 1 (20), have been developed.
As rapamycin has already been available for several decades,
our knowledge of signaling events associated with mTORC1
as well as its metabolic inputs and outputs is much broader as
compared with mTORC2. mTORC1 responds to growth fac-
tors (insulin), nutrients (amino acids, aa) and energy (ATP). In
response, mTORC1 activates anabolic processes (protein,
lipid, nucleotide synthesis) and blocks catabolic processes
(autophagy) to ultimately allow cellular growth (21). The insulin
signal is transduced to mTORC1 via the insulin receptor (IR),
and the insulin receptor substrate (IRS), which associates with
class I phosphoinositide 3-kinases (PI3Ks). Subsequent phos-
phatidylinositol 3,4,5 trisphosphate (PIP3) binding leads to
relocalization of the AGC kinases phosphoinositide-depen-
dent protein kinase 1 (PDK1) and Akt (also termed protein
kinase B, PKB) to the plasma membrane, where PDK1 phos-
phorylates Akt at T308 (22, 23). In response, Akt phosphory-
lates and inhibits the heterocomplex formed by the tuberous
sclerosis complex proteins 1 and 2 (TSC1-TSC2) (24, 25).
TSC1-TSC2 is the inhibitory, GTPase-activating protein for
the mTORC1-inducing GTPase Ras homolog enriched in
brain (rheb) (26–30), which activates mTORC1 at the lyso-
some. mTORC1 localization depends on the presence of aa,
which in a rag GTPase-dependent manner induce mTORC1
relocalization to lysosomes (31, 32). Low energy levels are
sensed by the AMP-dependent kinase (AMPK), which in turn
phosphorylates the TSC1-TSC2 complex (33) and raptor (34),
thereby inhibiting mTORC1.
mTORC1 phosphorylates its well-described downstream
substrate S6-kinase (S6K) at T389, the proline-rich Akt sub-
strate of 40 kDa (PRAS40) at S183, and the translational
repressor 4E-binding protein (4E-BP) at T37/46 (35–41). Un-
phosphorylated 4E-BP binds and inhibits the translation initi-
ation factor 4G (eIF4G), which within the eIF4F complex me-
diates the scanning process of the ribosome to reach the start
codon. Phosphorylation by mTORC1 inhibits 4E-BP’s inter-
action with eIF4E, thus allowing for assembly of eIF4F, and
translation initiation (42, 43). More recently, also the IR-acti-
vating growth factor receptor-bound protein 10 (Grb10) (44,
45), the autophagy-initiating Unc-51-like kinase ULK1 (46),
and the trifunctional enzymatic complex CAD composed of
carbamoyl-phosphate synthetase 2, aspartate transcarbam-
oylase, and dihydroorotase (47, 48), which is required for
nucleotide synthesis, have been described as direct mTORC1
substrates.
mTORC2 activation is mostly described to be mediated by
insulin, and this is mediated by a PI3K variant that is distinct
from the PI3K upstream of mTORC1 (49, 50). Furthermore,
mTORC2 responds to aa (5, 51). In response, mTORC2 phos-
phorylates the AGC kinases Akt at S473 (52–55), and serum
and glucocorticoid kinase SGK (56) and protein kinase C
alpha (PKCalpha) (7) within their hydrophobic motifs (57, 58),
to control cellular motility (5–7), hepatic glycolysis, and lipo-
genesis (59). In addition, mTOR autophosphorylation at
S2481 has been established as an mTORC2 readout in sev-
eral cell lines including HeLa cells (49).
Given the multiplicity of effects via which mTOR controls
cellular and organismal growth and metabolism, it is surpris-
ing that only relatively few direct mTOR substrates have been
established to date. Proteomic studies are widely used to
identify novel interactors and substrates of protein kinases.
Two studies have recently shed light on the interaction of
rapamycin and ATP-analog mTOR inhibitors with TSC2 inhi-
bition in mammalian cells (44, 45), and one study has analyzed
the effects of raptor and rictor knockouts in non-stimulated
cells (48).
In this work, we report a functional proteomics approach to
study mTORC1 substrates. We used an inducible raptor
knockdown to inhibit mTORC1 in HeLa cells, and analyzed
the effect in combination with insulin and aa induction by
quantitative phosphoproteomics using stable isotope labeling
by amino acids in cell culture (SILAC) (60). In parallel, we
purified endogenous mTOR complexes and studied the inter-
actome of mTOR by SILAC-MS. Through comparative data
evaluation, we identified acinus L as a potential novel aa/
insulin-sensitive mTOR substrate. We further validated acinus
L by co-immunoprecipitation and MS-enhanced kinase as-
says as a new direct mTORC1 substrate.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Lines—Phosphoproteome and interactome
experiments were performed in stably transduced inducible shRaptor
HeLa alpha-Kyoto cells (49). The other experiments were performed
in wild type HeLa alpha-Kyoto cells. All cells were cultivated in DMEM
(PAA, Pasching, Austria) supplemented with 10% FCS (PAA), and
1.5% L-glutamine (PAA). Insulin/aa induction was performed as de-
scribed (61). Knockdown of raptor was induced with 2 g ml1 of
doxycycline (Calbiochem, Merck, Darmstadt, Germany) for 2 or 3
days.
SILAC Labeling—shRaptor HeLa cells were labeled for at least 11
days in SILAC DMEM (PAA) supplemented with 10% dialyzed FCS
(PAA), 1.5% L-glutamine (PAA) and either with “heavy” lysine (146
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15N2 ) and arginine (84 mg/L;
13C6,
15N4), “medium” lysine
(146 mg/L; 4,4,5,5D4) and arginine (84 mg/L;
13C6), or “light” lysine
(146 mg/L) and arginine (84 mg/L). All amino acids were from Cam-
bridge Isotope Laboratories, Andover, MA. A minimal arginine-to-
proline conversion ( 3%) and virtually full incorporation of SILAC
amino acids into proteins ( 98.9%) were confirmed by LC/MS anal-
ysis (data not shown).
Antibodies—Antibodies for the analysis of mTOR signaling are
described elsewhere (49, 61). Acinus isoform L and its N-terminal
construct (acinus NT-myc-FLAG) were detected with AM26695AF-N
of Acris antibodies GmbH, Herford, Germany. FLAG was detected in
immunoblots with anti-FLAG rabbit antibody (Cell Signaling Technol-
ogy, Danvers, MA). All antibodies were used according to the manu-
facturers’ instructions. Monoclonal antibodies for mTOR (rat clone
3G6), raptor (rat clone 20D12) and control IgG (rat clone 7H8) for
immunopurifications (IPs) and immunoblots were generated in rats by
Dr. Elisabeth Kremmer, Helmholtz Zentrum, Munich, Germany as
described (62).
Cloning, Constructs, and Transfection—pCAGGS and pCAGGS-
acinus L were a kind gift from Prof. Tjuysoma, Osaka University, Suita,
Japan and Prof. Aoto, Ehime University, Toon-city, Japan, respec-
tively, and have been described (63).
pGEX-4T-1 Acinus NT-myc-FLAG, pCMV6-Acinus NT-myc-FLAG—
To create an N-terminal version of acinus L (corresponding to aa
1–523), pCAGGS-acinus L was used as a template. Acinus L NT
1–523 was amplified by using the following PCR primers: 5-AATTG-
GATCCATGTGGAGACGGAA-3 and 5-TATTTACGCGTGTCTGACT-
CAGGTTC-3. The PCR product was then cloned into pCMV6-entry
using BamH1 and Mlu1. To clone acinus L NT 1–523 into pGEX-4T-1,
acinus NT 1–523 was cut out with BamH1 and Not1 from pCMV6-
entry and inserted into pGEX-4T-1. The DNA sequence of the first 523
amino acids of acinus L with myc and FLAG-tag at the C terminus can
be found in the supplemental text.
Transfection of pCAGGS, pCAGGS-acinus L, pCMV6-entry, and
pCMV6-acinus NT-myc-FLAG into HeLa cells was performed with 15
g of each construct per 15 cm dish, using JetPEI reagent (PolyPlus,
Strasbourg, France) according to the manufacturer’s instructions.
Cells were harvested 48h after transfection.
Purification of GST-Acinus NT-myc-FLAG Protein—For the purifi-
cation of acinus L N-terminal, pGEX-4T-1 GST-acinus NT-myc-FLAG
was introduced into Rosetta competent cells ((Rosetta F-ompT
hsdSB (rB-mB) gal dcm pRARE23 (CamR), Novagen, Merck)). The
protein expression was induced by the addition of 1 mM IPTG
(PEQLAB, Erlangen, Germany) overnight at 37 °C. The bacteria were
harvested and lysed in 1 PBS (PAA) with Complete protease inhib-
itor (Roche, Mannheim, Germany) and benzonase (Merck Millipore)
with a homogenizer (Precellys 24, PEQLAB). The bacteria suspension
was subjected to 3  15 s pulses in tubes with glass beads (VK01/
VK05, PEQLAB). In between each pulse, the bacteria suspension was
placed on ice for 1 min. Insoluble matter was removed by centrifu-
gation at 1700 rpm for 1 h at 4 °C. The supernatant was incubated
with 4 ml of Glutathione Sepharose™ 4B (GE Healthcare, Freiburg,
Germany) for 1 h at 4 °C and for an additional 30 min at room
temperature (RT). The Sepharose was washed with 1 PBS until the
OD (280 nm) of the wash was below 0.05. GST-acinus NT-myc-FLAG
was eluted 2, each time with 20 mM glutathione (Sigma Aldrich, St.
Louis, MO) in 100 mM Tris-HCl pH 8 for 30 min at RT. The eluates were
combined and concentrated to about 2 mg/ml with a 5 kDa cut-off
Vivaspin concentrator (Sartorius Stedim Biotech, Go¨ttingen,
Germany).
Phosphoproteomics Sample Preparation—shRaptor HeLa cells
were washed 3with cold 1 PBS and lysed in sodium deoxycholate
lysis buffer (1% SDC (Sigma Aldrich), 50 mM ammonium bicarbonate
(Sigma Aldrich), PhosSTOP (Roche)). Protein concentrations were
measured using the Protein Assay Dye Reagent Concentrate (Bio-
Rad, Hercules, CA) according to the manufacturer’s protocol and
adjusted with lysis buffer. For immunoblotting, an aliquot of each
lysate was diluted in sample buffer (5 buffer: 6 ml glycerol, 0.6 ml
beta-mercaptoethanol, 1 g SDS, 3.75 ml 1 M Tris-HCl, pH 6.8, 2 mg
of bromphenol blue and 2 ml H2O). Immunoblotting was performed as
described (61). For MS analyses, equal amounts of protein from each
labeling state were pooled (total protein amount of 1–1.3 mg) and
digested with sequencing grade trypsin (1:50, Promega, Mannheim,
Germany) for 6 h at 37 °C. The digestion was stopped by adding
trifluoroacetic acid (TFA, LGC Standards, Wesel, Germany) to a final
concentration of 1%. Precipitating SDC was removed by centrifuga-
tion (max speed, tabletop centrifuge). The samples were desalted
using an Oasis® HLB Plus LP extraction cartridge (Waters, Milford,
MA). The cartridge was conditioned with 2  2 ml elution buffer (5%
formic acid, 90% acetonitrile (ACN)) followed by 2  2 ml wash buffer
(0.1% TFA). The sample was then applied to the cartridge and the
flow through was loaded again. The cartridge was washed with 3 ml
wash buffer and 2 ml H2O followed by elution with 2 ml elution buffer.
Eluates were lyophilized and stored at 80 °C.
Immunoprecipitation—IPs were performed essentially as described
(49). Cells of 70–90% confluence were lysed in 40 mM HEPES, 120
mM NaCl, 0.3% CHAPS, pH 7.5, supplemented with phosphatase
inhibitor mixture 2  3 (Sigma Aldrich) and Complete protease inhib-
itor (Roche). Per IP approach, lysates corresponding to one-half of a
15 cm plate were used. For IPs subjected to immunoblot or in vitro
kinase assays, lysates were precleared with 10 l Dynal Protein G
magnetic beads (Invitrogen, Life Technologies, Darmstadt, Germany)
per 1 ml lysate for 30 min at 4 °C. For each IP, 37 l Dynal Protein G
magnetic beads with 7.5 g antibody (anti mTOR clone 3G6, anti-rat
clone 7H8, anti-raptor clone 20D12 (all Dr. Elisabeth Kremmer), and
anti-FLAG M2 (Sigma-Aldrich)) were used. Magnetic beads were 3
shortly washed and 2 for 10 min with lysis buffer. Proteins were
eluted by incubation at 95 °C in 2 (for MS analysis) or 1 (for
immunoblot analysis) sample buffer.
In Vitro Kinase Assay—For mTOR in vitro kinase assays, co-IPs
with anti-raptor antibody clone 20D12 were performed. The mock IP
was carried out using anti-rat IgG clone 7H8 (kind gift of Dr. Elisabeth
Kremmer). The lysis buffer (40 mM HEPES, 120 mM NaCl, 0.3%
CHAPS, pH 7.5) was supplemented with 500 nM benzamidine (Sigma-
Aldrich) and 20 g/ml heparin (Sigma-Aldrich). Following raptor or rat
IPs, 26 l of the kinase reaction mix (MnCl2 4 mM, DTT 10 mM and
protease inhibitors without EDTA (Roche), heparin (2 g/ml, Sigma
Aldrich)) in lysis buffer and 1 g 4E-BP (ProSpec, East Brunswick, NJ)
or 12 g of purified acinus L N-terminal construct) were added to
each eluate. The reaction mix was incubated with 250 nM or 500 nM
Torin 1 (Tocris Bioscience, Bristol, UK) for 30 min at 30 °C with slight
agitation. For the conditions without Torin 1, DMSO (Sigma-Aldrich)
was added. The reaction was started by adding 4 l 1 mM ATP in lysis
buffer under shaking at 1,400 rpm and stopped after 60 min at 30 °C
with 1 sample buffer.
Coomassie Staining and In-gel Digestion—The samples of the ki-
nase assay were loaded onto 4–20% Tris-Glycine gels (Thermo Sci-
entific, Rockford, IL). Samples from mTOR IPs were loaded onto
NuPAGE® Novex® 4–12% Bis-Tris gels (Invitrogen, Life Technolo-
gies). After SDS-PAGE, proteins were stained with SimplyBlue™
SafeStain (Invitrogen, Life Technologies) according to the manufactur-
ers’ manual or by colloidal Coomassie Brilliant Blue G-250. For in-gel
digestion, the bands were cut out and destained with 50% buffer A
(10 mM ammonium bicarbonate in water) with 50% buffer B (100%
ACN). Proteins were reduced with 10 mM DTT in buffer A at 65 °C for
30 min, alkylated with 55 mM iodacetamide in buffer A at RT for 30 min
in the dark, and digested with trypsin (Promega) in buffer A at 37 °C
overnight or at 42 °C for 4 h. The peptides were eluted twice in 50%
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Buffer C (0.1% TFA in water) with 50% buffer B for 10 min in an
ultrasonic bath. The eluates were dried in vacuo and resuspended in
15 l buffer C for LC/MS measurement.
Strong Cation Exchange Chromatography—Tryptic peptides were
dissolved in SCX buffer A (5 mM potassium dihydrogen phosphate,
20% ACN (v/v), pH 2.8) and loaded onto a Polysulfoethyl-A column
(inner diameter 4.6 mm, 20 cm, 5 m, 200 Å, Dionex LC Packings/
Thermo Fisher Scientific, Dreieich, Germany) using a Dionex Ultimate
3000 UHPLC system. Peptides were isocratically separated for 10
min with 0% B followed by a three-step gradient of 0–30% SCX
buffer B (5 mM potassium dihydrogen phosphate, 20% ACN (v/v), 500
mM KCl, pH 2.8) in 50 min, 30–50% buffer B in 10 min and 50–100%
buffer B in 10 min. The column was washed with 100% buffer B for 5
min and re-equilibrated for 20 min with 100% buffer A. Twenty-eight
fractions at 2.1 ml were collected throughout the gradient. Twenty
microliters of each fraction were directly used for LC/MS analysis,
whereas the remaining digest was subjected to titanium dioxide (TiO2)
enrichment.
Titanium Dioxide Enrichment—TiO2 enrichment of phosphopep-
tides was essentially performed as described (64). Briefly, 10 l of a
25% slurry of TiO2 (MZ-Analysentechnik, Mainz, Germany) in 30
mg/ml 2,5-dihydroxybenzoic acid (Sigma Aldrich, St. Louis, MO) were
added to each SCX fraction and incubated for at least 30 min at 4 °C.
SCX fractions 1–28 were incubated 2, whereas fractions 1–10 were
incubated 3 with TiO2 beads. Following elution with 50 l 25%
ammonium hydroxide in 20% ACN and 50 l 25% ammonium hy-
droxide in 40% ACN, phosphopeptide samples were reduced to less
than 5 l and resuspended in 15 l of 0.1% TFA for LC/MS analysis.
High-performance Liquid Chromatography and Mass Spectrome-
try—Reversed-phase capillary HPLC separations were performed us-
ing the UltiMateTM 3000 RSLCnano system (Dionex LC Packings/
Thermo Fisher Scientific, Dreieich, Germany). Chromatography was
essentially performed as described previously (65) with slight modifi-
cations. For phosphoproteomics analysis, the HPLC system was
coupled to an LTQ-FT system (Thermo Fisher Scientific, Bremen,
Germany). Peptides were separated using an Acclaim® PepMapTM
analytical column (ID: 75 m  250 mm, 2 m, 100 Å, Dionex LC
Packings/Thermo Fisher Scientific) and a flow rate of 300 nL/min.
Samples were washed on a PepMapTM C18 -precolumn (ID: 0.3
mm  5 mm; Dionex LC Packings/Thermo Fisher Scientific) with
0.1% TFA for 30 min, which was subsequently switched in line with
the analytical column equilibrated in 95% solvent A (0.1% formic acid
(FA)) and 5% solvent B (0.1% FA, 86% ACN) for 20 min. Samples
were then separated by a gradient from 5% to 40% solvent B in 60
min, followed by a gradient from 40% to 95% solvent B in 7 min. The
column was washed for 3 min with 95% solvent B before re-equili-
bration. The LTQ-FT instrument was operated using a nano-flex ion
source with stainless steel emitters (Thermo Fisher Scientific, Bre-
men, Germany) and externally calibrated using standard compounds.
The general mass spectrometric parameters were as follows: spray
voltage, 1.8 kV; capillary voltage, 36 V; capillary temperature, 200 °C;
tube lens voltage, 145 V. For data-dependent MS/MS analyses, the
software XCalibur 2.0.7.0702 (Thermo Fisher Scientific) was used. MS
spectra ranging from m/z 370 to 1,700 were acquired in the ICR cell
at a resolution of 25,000 (at m/z 400). Automatic gain control (AGC)
was set to 2  106 ions and a maximum fill time of 1,000 ms. Multiply
charged peptide ions were selected for fragmentation in the linear ion
trap using a TOP5 method. The AGC of the LTQ was set to 30,000
ions with a maximum fill time of 500 ms. For MS/MS, a normalized
collision energy of 35% with an activation q of 0.25 and an activation
time of 30 ms was used. Multistage activation (MSA) was enabled
using neutral loss masses of 9, 18, 98, 49, and 32.7 Da and the
dynamic exclusion window was set to 65 s.
mTOR interactome data were acquired on an LTQ Orbitrap XL
system (Thermo Fisher Scientific) equipped with a nanoelectrospray
ion source and distal coated SilicaTips (FS360–20-10-D, New Objec-
tive, Woburn, MA). Chromatographic separations were performed as
described above with slight modifications as follows. Peptides were
washed on a C18 -precolumn with 0.1% TFA for 5 min and sepa-
rated on an Acclaim® PepMapTM analytical column (75 m  500
mm, 2 m, 100 Å, Dionex LC Packings/Thermo Fisher Scientific) at a
flow rate of 250 nL/min with a binary solvent gradient system con-
sisting of solvent A (0.1% FA) and solvent B (30% ACN, 50% meth-
anol (MeOH), 0.1% FA). For separation, the percentage of B was
raised from 15% to 72% in 45 min followed by an increase from 72%
to 100% B in 10 min. The column was washed with 100% B for 5 min
and re-equilibrated with 15% B for 15 min. Peptides were directly
transferred into the ion source. The instrument was operated as
described above for the LTQ-FT with slight modifications as follows:
spray voltage, 1.5 kV; capillary voltage, 44 V; tube lens voltage, 110 V.
The software XCalibur 2.1.0 SP1.116 (Thermo Fisher Scientific, Bre-
men, Germany) was used. Full scans (m/z 370 to 1,700) were acquired
in the orbitrap at a resolution of 60,000 (at m/z 400). AGC was set to
5  105 ions (max. fill time, 500 ms) in the orbitrap and to 30,000 ions
(max. fill time, 100 ms) in the LTQ. A TOP5 method was applied for
collision-induced dissociation of multiply charged peptide ions with
parameters as described above.
Samples from mTOR in vitro kinase assays were measured on the
RSLCnano/LTQ-FT for the first replicate and the RSLCnano/LTQ-
Orbitrap XL for the second replicate. Measurements were performed
essentially as described above. In brief, peptides were washed on a
C18 -precolumn with 0.1% TFA for 5 min and separated on an
Acclaim® PepMapTM analytical column (ID: 75 m  500 mm, 2 m,
100 Å, Dionex LC Packings/Thermo Fisher Scientific) at a flow rate of
250 nL/min. The analytical column was equilibrated in 99% solvent A
(4% dimethyl sulfoxide (DMSO), 0.1% FA) and 1% solvent B (4%
DMSO, 0.1% FA, 30% ACN, 50% MeOH) or 95% A and 5% B.
Samples were separated by a gradient of 1% (or 5% B) to 30%
solvent B in 85 min (or 75 min), followed by a gradient from 30% to
45% solvent B in 30 min (or 40 min), 45% to 70% solvent B in 35 min
and 70% to 99% solvent B in 5 min. Before re-equilibration for 15 min,
the column was washed for 5 min with 99% solvent B. Both instru-
ments were operated as described above. MSA was enabled on the
LTQ-FT (see above, dynamic exclusion 45 s) and on the LTQ-Orbitrap
XL using neutral loss masses of 98, 49, and 32.7 Da and a dynamic
exclusion window of 45 s.
Bioinformatics—For protein identification, peak lists were gener-
ated and searched against the Uniprot Human Proteome set (release
03.04.2013, 87,656 protein entries) and the contamination file sup-
plied with MaxQuant using Andromeda/MaxQuant 1.3.0.5 (66, 67).
The species was restricted to homo sapiens because only proteins
from human cells were analyzed. MaxQuant was operated using
default settings with slight modifications. Database searches were
performed with trypsin as proteolytic enzyme allowing up to two (IP),
three (in vitro kinase assay) or four missed cleavages (phosphopro-
teome). Oxidation of methionine as well as phosphorylation of serine,
threonine and tyrosine residues was commonly set as variable mod-
ification and carbamidomethlyation was set as fixed modification for
in vitro kinase assays and interactome analyses. Raw data were
recalibrated using the “first search” option of Andromeda with the full
database using a precursor mass tolerance of 20 ppm and a fragment
mass tolerance of 0.5 Da. Mass spectra were searched with Androm-
eda using default settings. The mass tolerance for precursor and
fragment ions was 5 ppm and 0.5 Da, respectively. For automated
quantification of protein groups, only “razor and unique” peptides and
a minimum ratio count of two were considered. In addition, “requan-
tify,” “filter labeled amino acids,” and “match between runs” with a 2
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min time window were enabled. Low-scoring peptides were ex-
cluded. A false discovery rate of 1% was applied on both peptide-
spectrum-matches (on modified peptides separately) and protein
lists. Protein ratios calculated by MaxQuant represent the median of
all peptide ratios of a distinct protein or protein group. The reported
ratio variability (in %) is the standard deviation of the ln-transformed
peptide ratios used to determine the protein ratio multiplied by 100
(66). For quantification of MS data from in vitro kinase assays, the
label-free protein quantification option in MaxQuant was enabled
using default settings. Only peptides with at least one unique peptide
(phosphoproteome and interactome data) or at least two unique
peptides (in vitro kinase assay) with a minimum length of seven aa are
reported in this work. If proteins were not distinguishable based on
the set of peptides identified, they were combined by MaxQuant and
listed as protein group. Further information about protein and peptide
identifications provided by MaxQuant are given in supplemental Ta-
bles S1A–S1C; S4A–S4C; S6B–S6G.
All raw data, including annotated (phospho-) peptide spectra, and
original MaxQuant result files have been deposited to the Proteome-
Xchange Consortium (http://proteomecentral.proteomexchange.org)
via the PRIDE partner repository (68) with the dataset identifiers
PXD001196 (phosphoproteome), PXD001244 (interactome) and
PXD001245 (in vitro kinase assay).
The number of proteins was counted based on the MaxQuant ID in
the protein groups table. Unique phosphopeptides were counted
based on the MaxQuant peptide ID in the Phospho(STY)sites table.
Phosphorylation sites scored with a MaxQuant localization probability
of  0.75 were considered “localized sites.” Sites with a localization
probability of  0.75 were counted as additional putative sites given
that the aa sequence in combination with the number of phosphate
moieties was not listed with localized sites elsewhere in the dataset.
Sites with ambiguous localization ( 0.75) are listed separately (sup-
plemental Table S2B). Normalized ratios provided by MaxQuant were
used and only phosphopeptides quantified in at least three out of four
replicates were considered for further analysis. For further analysis of
interactome data, non-normalized ratios were used and only protein
groups identified with at least two peptides and quantified in at least
two out of three replicates were considered. Ratios were log-trans-
formed (log10) and the mean log10 across all experiments as well as
the respective p values (interactome, one-sided t test; phosphopro-
teome, two-sided t test) were calculated. Phosphopeptides were
considered regulated with a regulation factor of at least 1.5 and a p
value below 0.05 for the insulin- and aa-dependent phosphopro-
teome. For raptor-dependent changes of protein phosphorylation
levels, a minimum fold change of 1.3 or 1.5 with a p value  0.05 was
applied to define two sets of candidates. Potential interaction part-
ners of mTOR were required to be identified with at least two peptides
and quantified with a mean ratio  5 or higher and a p value  0.01.
The quantification and normalization of immunoblots were per-
formed as described in (49). The signal of acinus L for “starvation”
was set to one and the relative intensity of the other signals was
calculated. For statistical analysis, a two-tailed paired t test was
performed using GraphPad prism 4 (GraphPad Software, Inc. La
Jolla, CA).
Raw files of the in vitro kinase assay were analyzed with an in-
house build software for peptide quantification based on extracted
ion chromatograms (XIC). The XIC of the S240 or S243 monophos-
phorylated peptide LSEGSQPAEEEEDQETPSR observed at m/z
1099.44 in the MS spectrum was extracted and the area under the
curve applying a 5% intensity threshold (AUC FW5PM, area under the
curve at full width at 5% peak height) was calculated. The respective
retention time of the phosphopeptide of interest was retrieved from
the evidence.txt file of the MaxQuant 1.3.0.5 search for each replicate
and a retention time window of 7 min (LTQ-FT) or 4 min (LTQ-Orbitrap
XL) was used for XIC calculation. The values for the AUC FW5PM
were normalized to the reported LFQ intensities of acinus L total
levels in the proteingroups.txt file. The highest normalized AUC
FW5PM value was set to 100% relative intensity for each replicate
(corresponding to raptor IP with GST-acinus NT-myc-FLAG).
GO term enrichment of the interactome data was performed with
the Cytoscape 3.1.1 (69) plugin ClueGO (version 2.1.3) (70). The
proteins significantly enriched in the mTOR versus mock IP were
analyzed against all identified proteins in the data set (reference data
set). The significance level was set to p  0.05 as determined by
hypergeometric test and Benjamini and Hochberg correction.
RESULTS
Analysis of the Amino Acid- and Insulin-Dependent mTORC1
Phosphoproteome—To identify mTORC1-dependent phos-
phorylation events, stably transduced shRaptor HeLa cells
were SILAC-labeled, and raptor knockdown was induced (Fig.
1A). Control cells and cells with raptor knockdown were
starved for serum and aa for 16 h. Afterwards, control and
shRaptor knockdown cells were stimulated for 30 min with aa
and insulin. In addition, another batch of control cells re-
mained starved. The experiment was performed in four inde-
pendent biological replicates, including a SILAC label switch.
Upon cell lysis and determination of protein content, aliquots
of each sample were analyzed by immunoblotting (Fig. 1B).
Insulinaa stimulation expectedly induced the mTORC2
readouts Akt-pS473 and mTOR-pS2481, as well as the
mTORC1 readout S6K-pT389. Upon shRaptor knockdown,
raptor protein levels were strongly reduced, and concomi-
tantly also the phosphorylation of S6K-T389 was inhibited,
whereas the mTORC2 readouts remained unaffected. For
global phosphoproteomics analysis, the three SILAC-en-
coded and differently treated samples were pooled in equal
protein amounts and, after quality control as shown in Fig.
1B, digested with trypsin and fractionated by SCX (Fig. 1A).
An aliquot of each SCX fraction was directly measured by
LC/MS. Phosphopeptides were enriched from SCX fractions
by TiO2 chromatography and subsequently analyzed by
LC/MS (Fig. 1A). By this approach, 4063 proteins were iden-
tified in the four replicates, of which 2708 were quantified by
MaxQuant (Fig. 2A, supplemental Table S1A). Of all identified
proteins, 1677 were phosphoproteins (756 quantified), corre-
sponding to 3542 unique phosphopeptides (3349 quantified),
and 4099 phosphosites (supplemental Table S2A). The ma-
jority of all sites (52%) could be localized with very high
confidence (probability 0.999) and further 38% were scored
with probabilities of more than 0.75. Only 9% (372) of all
identified sites could not be localized within the identified aa
sequence (probability  0.75) (Fig. 2B). Among the 3727
localized phosphorylation sites were 212, as yet, unknown
sites (supplemental Table S3).
To identify significantly regulated phosphopeptides, scatter
plots were generated by plotting the mean log10 SILAC ratios
of phosphopeptides quantified in at least three out of four
biological replicates of (1) starved versus insulinaa stimu-
lated cells and (2) insulinaa stimulated cells with and without
Combined Phosphoproteome and Interactome Analyses of mTORC1
2046 Molecular & Cellular Proteomics 14.8












raptor knockdown against the respective negative log10 p
values. With this approach, 128 phosphopeptides, corre-
sponding to 101 phosphoproteins, were considered regulated
on insulinaa stimulation with a fold-change  1.5 and a p
value  0.05 (Fig. 2C, supplemental Table S2A). Applying a
minimum fold-change of 1.5 or 1.3, a set of 14 respectively 34
phosphopeptides were found significantly regulated in raptor-
deficient cells, 13 of which responded to stimulation with
insulinaa (Fig. 2D, supplemental Table S2A). Based on this
analysis, we identified 31 phosphoproteins regulated by rap-
tor knockdown and, thus, in an mTORC1-dependent manner
(marked green in supplemental Table S2A).
Analysis of the mTOR Interactome—Next, we reasoned that
direct substrates of mTORC1 may not only be phosphorylated
in an insulin/aa- and raptor-dependent manner, but also in-
teract with mTOR. We therefore studied the interactome of
mTOR with the aim to identify those candidates that overlap
with the insulinaa- and mTORC1-specific phosphopro-
teome. To this end, we labeled HeLa cells by SILAC and
performed mTOR and mock IPs (Fig. 3A). Three independent
biological replicates were performed, with a label switch in
each. Aliquots of both the IP and lysate samples were ana-
lyzed by immunoblotting (Fig. 3B). As expected, the immuno-
precipitated protein mTOR and its interacting proteins raptor,
PRAS40 (mTORC1) and rictor (mTORC2) were detected in the
lysates and the mTOR IP, but not in the mock IP, used as a
negative control. To further delineate the mTOR interactome,
eluates from mTOR and mock IPs were mixed in equal vol-
umes, proteins were separated by SDS-PAGE, and analyzed
by LC/MS combined with MaxQuant (Fig. 3A). The mean log10
SILAC ratios of proteins identified in mTOR versus mock IPs
and quantified in at least two out of three biological replicates
were plotted against the negative log10 p values (Fig. 3C).
Proteins with a mean regulation ratio 5 and a p value 0.01
were considered significantly enriched (Fig. 3C, gray sector).
The mTOR interactome established in this work displays
known components common to both mTOR complexes
(mTOR, MTOR; mLST8, MLST8), as well as components spe-
cific to mTORC1 (raptor, RPTOR) or mTORC2 (rictor, RICTOR;
mSIN1, MAPKAP1) (Fig. 3C, orange dots), highlighting the
specificity and sensitivity of our approach. In total, 248 pro-
teins were found enriched with mTOR (supplemental Table
S4A). The overlay of the mTOR interactome with the raptor
and/or insulin/aa-dependent phosphoproteome yielded 14
proteins that were present in both datasets (Fig. 3D, supple-
mental Table S5), of which ACIN1 and EIF4G1 were at the
intersection of all three datasets. Interaction analysis using the
STRING 9.1 database (71) showed that eight of these proteins
have already been described as mTOR interactors (yet not all
of them as mTOR-dependent phosphorylation targets, see
discussion), whereas for six proteins (SPTBN1, BCLAF1,
ACIN1, SLK, AHNAK and PLEC) no interaction with mTOR is
known according to information provided by the STRING
database (date of September 2014). Thus, the latter proteins
represent new potential interaction partners of mTOR. GO-
term enrichment analysis showed that proteins regulating
RNA transport, metabolism, and translation were overrepre-
sented in the mTOR interactome (Fig. 3E). One of them, the
apoptotic chromatin condensation inducer in the nucleus
(ACIN1), in the following referred to as acinus L, which had so
FIG. 1. Experimental setup to study the mTORC1- and insulin/amino acid-dependent phosphoproteome. A, Inducible shRaptor HeLa
cells were differentially labeled by SILAC. Raptor knockdown was induced with doxycycline, as indicated. All cells were starved for serum and
amino acids (aa) for 16 h. Cells were stimulated for 30 min with aa and insulin, as indicated. Lysates were mixed equally and tryptic digests
were subjected to SCX fractionation. Twenty-eight fractions per biological replicate were collected and a small aliquot of each fraction was
analyzed by LC/MS. The remaining samples were subjected to titanium dioxide (TiO2)-based enrichment of phosphopeptides and analyzed by
LC/MS. Data of four biological replicates were quantitatively analyzed using MaxQuant. B, Immunoblot analysis was performed for all samples
subjected to MS analysis. To control for insulinaa stimulation, the mTORC2 readouts Akt-pS473 and mTOR-pS2481, as well as the mTORC1
readout S6K-pT389 were detected. shRaptor induction was confirmed by raptor detection.
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far not been functionally linked to mTOR, was identified with
high confidence as (1) insulin/aa- and raptor-dependent phos-
phorylation target, and (2) mTOR-interactor (Fig. 3D, marked
in orange). In our further work, we thus focused on the anal-
ysis of acinus L.
Acinus L is a Novel mTORC1 Substrate and Interactor—Our
central hypothesis was that proteins whose phosphorylation
depends on the presence of insulinaa and/or mTORC1, and
that interact with mTOR have a high probability to be direct
mTORC1 substrates. Our quantitative phosphoproteomics
analysis revealed acinus L-S240 as raptor-dependent phos-
phorylation site. Because acinus L protein levels were not
affected by raptor knockdown (supplemental Fig. S1A and
S1B), acinus L may likely be a direct target of mTORC1. In
order to determine whether mTORC1 indeed directly phos-
phorylates acinus L at S240, we designed a MS-enhanced in
vitro kinase assay. mTORC1 was immunopurified from HeLa
cells using a raptor-specific antibody (Fig. 4A). Acinus L con-
sists of 1341 aa with a theoretical and apparent molecular
mass of 151.9 and 220–250 kDa, respectively (63). As we
needed the unphosphorylated protein as a substrate for ki-
nase assays, we aimed to purify native acinus L from a bac-
terial expression system. Because of its large size, bacterial
expression and protein purification of recombinant acinus L is
challenging. We therefore cloned an N-terminal acinus L trun-
cation construct (acinus L 1–523), comprising aa residues
1–523 with an N-terminal GST tag and a C-terminal myc-
FLAG-tag (cumulative theoretical mass of 87 kDa), into a
bacterial expression vector. Acinus L 1–523 was purified by
GST pulldown and used as a substrate in in vitro kinase
assays with immunopurified mTORC1 (raptor-mTOR). In ad-
dition, we performed the following controls: (1) the specific
mTOR inhibitor Torin 1 (20) was added to the reaction at two
different concentrations, (2) immunopurified raptor-mTOR
was incubated without addition of acinus L 1–523, and (3)
acinus L 1–523 was incubated with a mock IP (instead of
immunopurified raptor-mTOR complexes). The presence of
the respective proteins in each reaction was tested by immu-
noblotting (Fig. 4A). To further confirm the specificity of the
approach, the same reactions were carried out with the
known mTORC1 substrate 4E-BP1 followed by immunoblot-
ting (Fig. 4B). As expected, 4E-BP1 was phosphorylated at
T37/46 in the presence of mTORC1, and phosphorylation was
reduced by Torin 1, showing that the reaction was specifically
exerted by mTOR kinase. As no signals were observed in the
negative controls (i.e. mock IP, or no addition of 4E-BP1), the
FIG. 2. The phosphoproteome after insulin and amino acid stim-
ulation with and without raptor knockdown. A, Numbers of iden-
tified and quantified (phospho-)proteins and (phospho-)peptides
obtained by SILAC-MS analyses of four independent biological rep-
licates. The number of phosphopeptides was calculated based on the
number of MaxQuant peptide IDs in the Phospho(STY)sites table. B,
Localization probabilities calculated for all 4,099 phosphorylation
sites reported by MaxQuant. Only sites with a localization probability
of  0.75 were considered localized. C, D, Mean log10 ratios of
phosphopeptides in starved versus restimulated samples and in re-
stimulated cells with and without raptor knockdown plotted against
negative log10 p values (Student’s t test). Phosphopeptides were
considered regulated with a regulation factor of at least 1.5 and a p
value below 0.05 for the insulin- and aa-dependent phosphopro-
teome (gray sector). For raptor-dependent changes of protein phos-
phorylation levels, a minimum fold change of 1.3 (yellow and gray
sector) or 1.5 (gray sector) with a p value 0.05 was applied to define
two sets of candidates.
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FIG. 3. The mTOR interactome. A, Experimental setup of the mTOR interactome analysis. HeLa cells were differentially labeled with SILAC
amino acids and subjected to mock or mTOR immunopurification (IP) experiments. Eluates were mixed in equal ratios and proteins were
separated by SDS-PAGE followed by in-gel digestion with trypsin and LC/MS analysis. Data obtained from three biological replicates including
a SILAC label switch were analyzed using MaxQuant. B, Immunoblot analysis of samples obtained from mock and mTOR IPs as depicted in
A. The mTOR IP yielded intact mTOR complexes as shown by co-immunoprecipitation of the known interaction partners raptor, rictor, and
PRAS40. C, Mean log10 ratios of proteins detected in mTOR versus mock IP experiments and quantified in at least two out of three biological
replicates were plotted against the negative log10 p value (Students t test). Proteins were considered significantly enriched with a mean ratio
5 and a p value  0.01 (sector highlighted in gray). Core components of mTOR complex 1 and 2 are marked in orange (mTOR, raptor, rictor,
mLST8, and mSIN1). Proteins that were also found regulated in our phosphoproteome analysis are marked in blue. Raptor was found regulated
in both analyses (marked in blue orange) D, Overlap of proteins enriched with mTOR, and with changes in phosphorylation levels following
restimulation and raptor knockdown. Proteins marked in light blue are sensitive to amino acid and insulin treatment, whereas proteins depicted
in orange are responsive to raptor knockdown. E, Gene Ontology (GO) enrichment analysis of proteins enriched with mTOR for the three main
GO domains cellular compartment, molecular function, and biological process. The length of the bar represents the log10 Benjamini-Hochberg
corrected p value. The numbers represent the percentage of associated genes for each term.
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signal detected by the phospho-specific antibody was con-
firmed to be specific for 4E-BP1 and mTORC1. Using high
resolution MS, we next studied phosphorylation of acinus L
1–523 by immunopurified mTORC1. MS-enhanced mTORC1
kinase assays were performed in two independent replicates,
yielding comparable results (Fig. 4C). We detected the pep-
FIG. 4. Acinus L is directly phosphorylated by mTOR at S240/S243. A, B, Immunoblots of the mTOR kinase assay. To purify mTORC1
kinase, raptor IPs were performed. GST-tagged acinus NT-myc-FLAG served as substrate, and 4EBP1, known to be phosphorylated by mTOR
on T37 and T46, served as a positive control. To test the specificity of the kinase reaction, the mTOR inhibitor Torin 1 was used in two different
concentrations as indicated. The mock IP served as an additional negative control. C, Relative intensities of the monophosphorylated peptide
LSEGSQPAEEEEDQETPSR of acinus L for all indicated conditions in two independent replicates. The dashed line indicates the cut-off for
background phosphorylation as determined by the mock IP with acinus NT-myc-FLAG. D, E, Annotated MS/MS spectra of the monophos-
phorylated peptide LSEGSQPAEEEEDQETPSR of acinus L with localization of the phosphate moiety to S240 and S243, respectively. The
zoom-in shown in D highlights the presence of the y16 ion (m/z 1788.91) specific for pS240, which is absent in E. *b, *y: fragment ions with
neutral loss of H3PO4 (97.9768 u).
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tide LSEGSQPAEEEEDQETPSR of acinus L 1–523 only in its
monophosphorylated forms with the phosphate group lo-
cated either at S240 or S243 (Fig. 4D and 4E, supplemental
Fig. S2). Because both phosphoforms (pS240, pS243)
showed the identical elution profile under the conditions ap-
plied here, relative quantification was performed based on the
signal detected for both phosphoforms (supplemental Fig.
S3). Our results showed acinus L 1–523 to be specifically
phosphorylated in an mTORC1-dependent manner at S240/
S243 (Fig. 4C–4E). These findings are in agreement with the
raptor-dependent phosphorylation sites of acinus L identified
in our phosphoproteome analysis (supplemental Table S2A, id
3676). Thus, based on our in vivo and in vitro data, we pro-
pose that mTORC1 directly phosphorylates acinus L at
S240/S243.
Finally, we sought to confirm whether endogenous acinus L
interacts with mTORC1. Indeed, acinus L was specifically
detected in an mTOR IP but not in a mock IP (Fig. 5A). To
further characterize the interaction, we overexpressed FLAG-
acinus L and acinus NT-myc-FLAG or transfected the empty
control plasmids in mammalian cells (Fig. 5B), performed
FLAG IPs, and detected mTOR and raptor. We found that the
mTOR-raptor complex copurified with both full length FLAG-
acinus L and truncated acinus NT-myc-FLAG (Fig. 5C). Thus,
we conclude that the mTORC1-acinus interaction domain and
the mTORC1 substrate sites are both located within the N-
terminal region of acinus L.
DISCUSSION
In this work, we characterized the insulinaa- and raptor-
dependent phosphoproteome and identified the overlap with
the mTOR interactome by a combined quantitative phospho-
proteomics and interactomics approach. Three previous pro-
teomic studies have analyzed different aspects of mTOR sig-
naling in mammalian cells. First, Hsu et al. (44) analyzed
insulin stimulation in combination with rapamycin or Torin 1
(ATP-analog mTOR inhibitor) treatment in HEK293 fibroblasts,
as well as Torin 1 treated TSC2 knockout (KO) mouse embry-
onic fibroblasts (MEFs) by quantitative MS using iTRAQ. Sec-
ond, Robitaille et al. (48) studied raptor and rictor KO MEFs
without stimulation by a SILAC-based quantitative proteomics
approach. And third, Yu et al. (45) analyzed TSC2 KO MEFs in
combination with rapamycin treatment, and insulin-induced
MEFs in combination with rapamycin and/or Ku-0063794
(ATP-analog mTOR inhibitor) using SILAC. In our study, we
followed a SILAC-based phosphoproteomics approach that
takes advantage of the specificity of a direct raptor knock-
down combined with mTOR-induction by insulin and aa in
HeLa cells. Moreover, to obtain a comprehensive picture of
mTOR signaling, we delineated the mTOR interactome by
SILAC-MS, which allowed us to suggest acinus L as a novel
direct mTORC1 substrate. In general, our data correlate well
with the three previous mTOR proteome studies, as dis-
cussed in more detail in the following. Hsu et al. (44) reported
127 Torin 1-sensitive phosphopeptides in HEK293T, and 231
FIG. 5. Acinus L is a novel mTOR interactor. A, Immunoblot analysis of mTOR and mock immunopurifications (IPs). The mTOR IP yielded
intact mTOR complex 1 as shown by copurification of raptor. Acinus L specifically copurified with mTOR. B, Overview of the acinus constructs
used in C. The FLAG-tag is shown in orange, the myc-tag in blue. C, Immunblot analysis of IPs with anti-FLAG antibody. The immunblots show
an interaction of mTOR and raptor with acinus L and acinus NT-myc-FLAG. Acinus L was detected with an antibody against the N terminus
of acinus L and the FLAG epitope, respectively.
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in MEFs by calculating the median absolute deviation (MAD)
to determine outliers for two out of four replicates. If we follow
the same statistical approach, we determine 120 to 200
mTORC1-dependent phosphopeptides as outliers depending
on the replicates chosen in our data set. Application of strin-
gent criteria as reported in this work resulted in a set of 34
raptor-dependent phosphopeptides.
We identified mTORC1 target sites in both 40S ribosomal
protein S6 (RPS6) and raptor. RPS6 is the best described S6K
substrate, and is phosphorylated at S235, S236, and S240
(72–74). RPS6 phosphorylation, as determined by phospho-
proteomics, was reported by Yu et al. (45) to be sensitive to
mTOR inhibitors. The mTORC1 core component raptor (9, 10)
is phosphorylated at S859 and S863 by mTOR (75, 76). The
identification of these bona fide mTORC1-dependent phos-
phorylation sites, as well as the identification of raptor in our
mTOR interactome, underscore the validity of our approach
for the study of mTORC1 signaling. In addition, we report the
cap-component and eukaryotic translation initiation factor
4GI (eIF4GI) as mTOR interactor, and identified eIF4GI phos-
phorylation at S1185 to be mTORC1-dependent. Interest-
ingly, eIF4GI-S1185 phosphorylation was down-regulated by
insulinaa, but induced by raptor knockdown, suggesting
that this change is mediated by an mTORC1-dependent
phosphatase. However, this site may also be phosphorylated
by mTOR as Robitaille et al. (48) found the synthetic eIF4GI
peptide SFSKEVEER to be phosphorylated by recombinant
mTOR in an in vitro kinase assay. Our findings also comple-
ment data from the Sonenberg lab that reported over a dec-
ade ago that serum-induced modulation of eIF4GI phosphor-
ylation at Ser1108, Ser1148, and Ser1192 is mediated by
PI3K and mTOR signaling (77). eIF4GI mediates mTOR-de-
pendent translation, proliferation and autophagy inhibition,
and eIF4GI inhibition phenocopies nutrient starvation and
mTOR inhibition (78). Thus, eIF4GI is a major downstream
effector of mTORC1, which is corroborated by our data.
Apart from translational control, negative feedback regula-
tion of insulin signaling is another major mTORC1 output,
involving IRS phosphorylation by S6K downstream of
mTORC1 and subsequent destabilization of the IRS protein
(79–81). This mechanism in conjunction with Grb10 phosphor-
ylation by mTORC1 (44, 45) contributes to a well described
negative feedback loop (2) that renders the IR complex re-
fractory to insulin when mTORC1 is active. IRS exists in two
isoforms, and phosphorylation of IRS-2 is far less studied than
for IRS-1. Fritsche et al. (82) have shown that insulin-induced
phosphorylation at IRS-2-S675 is mTOR-dependent, and Yu
et al. (45) reported IRS-2 phosphorylation to be sensitive to
mTOR-inhibitors. In this work, we report insulin-induced
phosphorylation of IRS-2 at T527 to be raptor-dependent,
possibly adding to an mTORC1-dependent negative feed-
back mechanism.
As a result of our combined phosphoproteome and inter-
actome analysis, we identified acinus L as a potential direct
mTORC1 substrate. Acinus L was significantly enriched with
mTOR, and phosphorylation of acinus L at S240/S243 was
insulin- and raptor-dependent in HeLa cells. This phosphory-
lation site appeared as Torin 1- and rapamycin-sensitive in one
replicate of the phosphoproteome study by Hsu et al. (44).
Another phosphopeptide (SQSPSPPPLPEDLEK, acinus L-
pS391) of acinus L has been identified by Robitaille et al. (48)
as an mTORC2 substrate in mouse embryonic fibroblasts by
phosphoproteomics and a peptide array-based in vitro kinase
assay. Neither of the two previous studies reported binding
studies for acinus L. In this work, the overlay of the mTOR
phosphoproteome and interactome in human cells led to the
identification of acinus L as a prime candidate for both mTOR
binding and mTORC1-dependent phosphorylation. In addi-
tion, our study identified further novel insulin-dependent
phosphotargets and mTOR interactors (Fig. 3D, supplemental
Tables S2, S4, and S5), which may link to mTORC2 substrates
and/or insulin dependent mTORC1 and mTORC2 regulation.
We chose to focus here on mTORC1-specific phosphotargets
and interactors, and we thus proceeded to validate acinus L
as a new direct substrate of mTORC1.
Our functional analyses confirmed that acinus L is a direct
mTOR interactor, which is specifically phosphorylated at
S240/243 by mTORC1. Hence, our initial hypothesis that di-
rect mTOR interactors whose phosphorylation is raptor-de-
pendent are direct mTORC1 targets turned out to be valid.
Furthermore, our data provide a rich source for follow-up
studies of mTOR interactors and substrates, and the experi-
mental strategy outlined here is well-suited to delineate mTOR
substrate networks under different metabolic conditions and
in different cell types in future work.
What may be the functional connection between acinus L
and mTORC1? Acinus L is a component of the apoptosis- and
splicing-associated protein (ASAP) complex, which associ-
ates with the exon junction complex (EJC) (83, 84). The EJC
plays an important role in mRNA surveillance by binding up-
stream of exon–exon junctions of newly spliced mRNA to
ensure the accuracy and efficiency of eukaryotic gene expres-
sion in the first, pioneer round of protein synthesis. Thus,
deposition of EJCs within the ORF correlates with enhanced
cytoplasmic polysome association of spliced mRNAs and an
increased translational yield (85). Of note, activated S6K con-
tributes to this process, as when recruited to newly spliced
mRNA by the EJC protein SKAR, S6K1 increases the trans-
lation efficiency (84). In addition, when bound to the 3-UTR of
mRNAs (85), the ASAP complex and the EJC function to-
gether in nonsense-mediated decay (86) to eliminate mRNAs
that would prematurely terminate translation.
Acinus L belongs to the “peripheral” components of the
EJC (87). Interestingly, the EJC core component mago nashi
homolog 2 (MAGOHB) (88), the peripheral EJC component
pinin and the NMD factors UPF1, UPF2, and UPF3B (85)
scored also as highly significant in our mTOR-interactome
analysis. Further core and peripheral EJC components (i.e.
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histone deacetylase complex subunit SAP18, RNA-binding
protein with serine-rich domain 1 (RNPS1), eukaryotic initia-
tion factor 4A-III (eIF4AIII), RNA-binding protein 8A (Y14), and
metastatic lymph node gene 51 protein (MLN51)) were also
found enriched with mTOR but did not pass our stringent filter
criteria for candidate proteins. The high representation of EJC
components in our mTOR interactome together with the dis-
covery that acinus L is a direct mTORC1 substrate strongly
suggest that, under insulin and aa stimulation, the EJC com-
plex may provide a framework for the regulation of the pioneer
round of translation by mTORC1. Acinus L may be a compo-
nent that transmits a signal from mTORC1 to the EJC, thus
contributing to the enhanced translation efficiency of spliced
over nonspliced mRNAs (84). In line with this, the oncogenic
kinase Akt, which is upstream mTORC1, has been shown to
bind acinus L in a PI3K-dependent manner (89). Acinus L itself
is strongly overexpressed and phosphorylated in human pa-
tients with myeloid hematological malignancies (87), and the
ACIN1 gene is hypermethylated in lung carcinoma (90) and
found mutated in up to 8% of the analyzed tumors depending
on the study and tumor entity (91). Thus, we advocate further
investigation of acinus L to explore its potential as molecular
target downstream of mTORC1 in cancers.
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